Drug Trial Radar · NCT05039840
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
109
Actual
Start
Nov 10, 2021
Primary completion
Sep 4, 2026
Study completion Nov 24, 2026
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Sep 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with placebo in the treatment of participants aged 18 to 70 years with active Systemic Lupus Erythematosus (SLE). Study details include: * Study duration: 36 weeks * Treatment duration: 24 weeks * Visit frequency: every 2 weeks
Conditions
- Systemic Lupus Erythematosus
Interventions
SAR441344 IVDrug
Pharmaceutical form: solution Route of administration: Intravenous infusion
SAR441344 SCDrug
Pharmaceutical form: solution Route of administration: subcutaneous injection
Placebo IVDrug
Pharmaceutical form: solution Route of administration: Intravenous infusion
Placebo SCDrug
Pharmaceutical form: solution Route of administration: subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants who achieved a Systemic Lupus Erythematosus Responder Index (SRI-4) response at Week 24.Time frame: At Week 24
Locations
73 sites in 16 countries. Site status is shown where the registry gives one.
Accel Research Sites Network - Birmingham- Site Number : 8400003
Vestavia Hills, Alabama
AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Chandler- Site Number : 8400026
Chandler, Arizona
Arizona Arthritis & Rheumatology Associates - South Vineyard Avenue- Site Number : 8400022
Mesa, Arizona
Arizona Arthritis & Rheumatology Research - Sun City- Site Number : 8400027
Sun City, Arizona
AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Tucson Southeast- Site Number : 8400023
Tucson, Arizona
Saint John's Physician Partners- Site Number : 8400015
Santa Monica, California
Millennium Clinical Trials - Simi Valley- Site Number : 8400004
Simi Valley, California
Omega Research Consultants - Debary - North Charles Richard Beall Boulevard- Site Number : 8400002
DeBary, Florida
Vitalia Medical Research - Margate- Site Number : 8400039
Margate, Florida
Innovia Research Center- Site Number : 8400037
Miramar, Florida
Integral Rheumatology and Immunology Specialists- Site Number : 8400014
Plantation, Florida
Infigo Clinical Research- Site Number : 8400016
Sanford, Florida
Inspire Santa Fe Medical Group- Site Number : 8400019
Santa Fe, New Mexico
Columbia University Irving Medical Center- Site Number : 8400009
New York, New York
RAO - Rheumatology Associates of Oklahoma- Site Number : 8400013
Oklahoma City, Oklahoma
Private Practice - Dr. Ramesh C. Gupta I- Site Number : 8400008
Memphis, Tennessee
Tekton Research - West Gate- Site Number : 8400001
Austin, Texas
Precision Comprehensive Clinical Research Solutions - Colleyville- Site Number : 8400017
Colleyville, Texas
Lone Start Arthritis & Rheumatology Associates- Site Number : 8400025
Fort Worth, Texas
Prolato Clinical Research Center- Site Number : 8400005
Houston, Texas
AARA Clinical Research - Lone Star Arthritis & Rheumatology Associates - Irving- Site Number : 8400024
Irving, Texas
West Texas Clinical Research- Site Number : 8400018
Lubbock, Texas
Investigational Site Number : 0320006
Buenos Aires, Argentina
Investigational Site Number : 0320001
Buenos Aires, Argentina
Investigational Site Number : 0320004
Buenos Aires, Argentina
Investigational Site Number : 0320002
Buenos Aires, Argentina
Investigational Site Number : 0320008
Berazategui, Buenos Aires, Argentina
Investigational Site Number : 0320003
San Miguel de Tucumán, Tucumán Province, Argentina
IBCC - Núcleo de Pesquisa e Ensino- Site Number : 0760007
São Paulo, Brazil
Centro Paulista de Investigaçăo Clínica - CEPIC- Site Number : 0760004
São Paulo, Brazil
Centro de Estudos em Terapias Inovadoras- Site Number : 0760002
Curitiba, Paraná, Brazil
LMK Servicos Medicos- Site Number : 0760001
Porto Alegre, Rio Grande do Sul, Brazil
Fundação Faculdade Regional de Medicina de São José do Rio Preto- Site Number : 0760006
São José do Rio Preto, São Paulo, Brazil
Investigational Site Number : 1520002
Osorno, Los Lagos Region, Chile
Investigational Site Number : 1520003
Talca, Maule Region, Chile
Investigational Site Number : 1520004
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1520001
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 2680005
Tbilisi, Georgia
Investigational Site Number : 2680004
Tbilisi, Georgia
Investigational Site Number : 2680001
Tbilisi, Georgia
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.